AlphaYou
Overview
Smart money at a glance
Filings to Oct 2, 2026Net selling: insiders sold $8.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$8.2M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Oct 1- Open
- $88.64
- 52-wk high
- $110.17
- High
- $95.08
- 52-wk low
- $15.86
- Low
- $88.00
- Prev close
- $84.72
- Mkt cap
- $7.85B
- Volume
- 2.10M
- Beta
- 3.00
- P/S
- 650.2x
- P/B
- 8.1x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -23.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about SYRE filings
Are insiders buying or selling Spyre Therapeutics Inc. (SYRE) stock?
Net selling: insiders sold $8.2M and bought $0 of SYRE stock on the open market in the 90 days to Oct 2, 2026, according to SEC Form 4 filings. $8.2M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Burrows, Scott L (Chief Financial Officer), who sold $3M. The latest filing was on Sep 4, 2026.
Which members of Congress have traded SYRE recently?
None. No member of Congress disclosed a SYRE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this SYRE smart-money data?
This summary uses filings available on Oct 2, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- MW
Marshall Wace
$81.0M
added
- BO
Bank of America
$48.2M
added
- JC
JPMorgan Chase
$42.4M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in SYRE right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 49.3% above what analysts expected.
Earnings per share
-$0.71 expected
Reports Nov 3, 2026, in 32 days
Estimates as of Oct 1, 2026
EPS expected
-$1.53 to -$0.66
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $90.5M | $0 | $0 |
| Cost of what it sold | $45.2M | $45.2M | — | — |
| Gross profit | -$45.2M | $45.2M | — | — |
| What it spent | ||||
| Research and development | $45.2M | $44.6M | $60.4M | $65.5M |
| Sales and admin | $11.6M | $12.5M | $15.2M | $16.1M |
| Other operating costs | -$45.2M | $45.2M | -$30.0M | -$40.0M |
| Total operating expenses | $11.6M | $102.4M | $45.6M | $41.6M |
| What was left | ||||
| Operating profit | -$56.9M | -$57.2M | -$45.6M | -$41.6M |
| Profit before tax | -$11.2M | -$62.5M | -$69.0M | -$36.2M |
| Tax | — | $30.0K | — | — |
| Net profit | -$11.2M | -$62.5M | -$69.0M | -$36.2M |
| EBITDA | -$11.2M | -$62.5M | -$75.6M | -$36.2M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace